Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.34 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102331 | 0.68 | PDPK1 (0.59) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL1467709 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL1389231 | 0.67 | HSP90AA1 (0.42) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL222697 | 0.67 | HSP90AA1 (0.42) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL31556353 | 0.66 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL28154527 | 0.66 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL30534095 | 0.66 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL30632310 | 0.66 | PDPK1 (0.56) | HSP90AA1RAB9APDPK1ADORA2AADORA1 | |
| SCHEMBL30511083 | 0.66 | — | — | |
| SCHEMBL2710465 | 0.65 | KDM4E (0.48) | RAB9ALOXL2CYP2A6CYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012639-B2 | Copper complexes for optoelectronic applications | CYNORA GMBH (DE) | 2015-04-21 | — | — | US | claimed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | claimed |
| EP-2188255-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | AstraZeneca AB (SE) | 2010-05-26 | — | — | EP | claimed |
| WO-2009027746-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | WO | claimed |
| EP-1040100-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | Pfizer Products Inc. (US) | 2000-10-04 | — | — | EP | claimed |
| WO-1999023076-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | claimed |
| EP-0714397-A4 | — | — | 1996-06-26 | — | — | EP | claimed |
| EP-0714397-A1 | PHENETHYLAMINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-06-05 | — | — | EP | claimed |
| WO-1995005386-A1 | PHENETHYLAMINE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-02-23 | — | — | WO | claimed |
| US-20240158347-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | LB PHARMACEUTICALS INC. | 2024-05-16 | — | — | US | disclosed |
| US-20240150283-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | LB PHARMACEUTICALS INC. | 2024-05-09 | — | — | US | disclosed |
| US-20240115547-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | LB PHARMACEUTICALS INC. | 2024-04-11 | — | — | US | disclosed |
| EP-4340825-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | LB Pharmaceuticals Inc. (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11827645-B2 | Spiro-γ-Lactams, and preparation method and use thereof | Chongqing University of Arts and Sciences (CN) | 2023-11-28 | — | — | US | disclosed |
| EP-0922036-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GmbH (DE) | 1999-06-16 | — | — | EP | disclosed |
| WO-1999023077-A1 | INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN THERAPEUTICALLY ACTIVE COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999023076-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS BASED ON INDAZOLE BIOISOSTERE REPLACEMENT OF CATECHOL IN PDE4 INHIBITORS | PFIZER PRODUCTS INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998006704-A1 | ARYLALKANOYL PYRIDAZINES | MERCK PATENT GMBH (DE) | 1998-02-19 | — | — | WO | disclosed |
| EP-0039892-B1 | SUBSTITUTED PHENYL ETHERS | CIBA-GEIGY AG (CH) | 1986-12-30 | — | — | EP | disclosed |
| US-4559354-A | ADRENERGIC BLOCKING AGENTS AND STIMULANTS; CARDIOTONIC, ANTIARRHYTHMIA AND INOTROPIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1985-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115547-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | HTR2A, HTR7, HTR3B | HSP90AA1 2554/4885RAB9A 933/4885PDPK1 1514/4885 |
| US-20240150283-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | HTR2A, HTR2C, HTR2B | HSP90AA1 2826/4885RAB9A 448/4885PDPK1 1296/4885 |
| US-11827645-B2 | Spiro-γ-Lactams, and preparation method and use thereof | KRAS, CEL, STS | HSP90AA1 578/4885RAB9A 107/4885PDPK1 1545/4885 |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | HSP90AA1 2380/4885RAB9A 1639/4885PDPK1 1063/4885 |
| US-20240158347-A1 | PSYCHOTROPIC AGENTS AND USES THEREOF | HTR2A, HTR2C, HTR2B | HSP90AA1 2826/4885RAB9A 448/4885PDPK1 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.